<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="used to identify potent drugs for SARS-CoV-2. •Atazanavir, remdesivir, and" exact="Kaletra" post="were predicted to inhibit SARS-CoV-2. •Rapamycin and tiotropium bromide"/>
 <result pre="remdesivir, and Kaletra were predicted to inhibit SARS-CoV-2. •Rapamycin and" exact="tiotropium" post="bromide may also be effective for SARS-CoV-2. Abstract The"/>
 <result pre="against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM)," exact="efavirenz" post="(199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM)."/>
 <result pre="3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM)," exact="ritonavir" post="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir,"/>
 <result pre="addition, we also found that several antiviral agents, such as" exact="Kaletra" post="(lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2."/>
 <result pre="SARS-CoV-2. Keywords COVID-19 SARS-CoV-2 Coronavirus MT-DTI Deep learning Drug repurposing" exact="Atazanavir" post="1 Introduction Coronaviruses (CoVs), belonging to the family Coronaviridae,"/>
 <result pre="analysis. The SARS-CoV-2 3C-like proteinase was predicted to bind with" exact="atazanavir" post="(Kd 94.94 nM), followed by remdesivir, efavirenz, ritonavir, and"/>
 <result pre="studies have been identified. For example, a docking study of" exact="lopinavir" post="along with other HIV proteinase inhibitors of the CoV"/>
 <result pre="HIV proteinase inhibitors of the CoV proteinase (PDBID 1UK3) suggests" exact="atazanavir" post="and ritonavir, which are listed in the present prediction"/>
 <result pre="the CoV proteinase in line with the inhibitory potency of" exact="lopinavir" post="[27]. According to the prediction, viral proteinase-targeting drugs were"/>
 <result pre="DTI prediction Kd in nM MT-DTI Rank out of 3411" exact="Atazanavir" post="COC( 000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000"/>
 <result pre="CC CC C4 113.13 70 Efavirenz* O C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 199.17 116" exact="Ritonavir" post="CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1 204.05 119 Dolutegravir CC1CCOC2Cn3cc(C( O)NCc4ccc(F)cc4F)c("/>
 <result pre="C C[C@H]1C[C@]1(NC( O)[C@@H]1C[C@@H]2CN1C( O)[C@H](C(C)(C)C)NC( O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C( O)NS( O)( O)C1CC1 8.69 40" exact="Ganciclovir" post="Nc1nc( O)c2ncn(COC(CO)CO)c2[nH]1 11.91 58 Remdesivir* CCC(CC)COC( O)[C@H](C)N[P@]( O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2 CC"/>
 <result pre="O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2 CC C3N2N CN C3N)O)O)OC4 CC CC C4 20.17 93" exact="Atazanavir" post="COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 21.83 100 Daclatasvir COC("/>
 <result pre="20.17 93 Atazanavir COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 21.83 100" exact="Daclatasvir" post="COC( O)NC(C( O)N1CCCC1c1ncc(—c2ccc(—c3ccc(-c4cnc(C5CCCN5C( O)C(NC( O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C 23.31 107 Acyclovir Nc1nc("/>
 <result pre="O)N1CCCC1c1ncc(—c2ccc(—c3ccc(-c4cnc(C5CCCN5C( O)C(NC( O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C 23.31 107 Acyclovir Nc1nc( O)c2ncn(COCCO)c2[nH]1 26.66 122" exact="Etravirine" post="Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br 33.09 151 Entecavir* C C1[C@@H](n2cnc3c( O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO 52.83 215"/>
 <result pre="C CC1CC1(NC( O)C1CC(Oc2ncc(OC)c3ccc(Cl)cc23)CN1C( O)C(NC( O)OC(C)(C)C)C(C)(C)C)C( O)NS( O)( O)C1CC1 78.36 291" exact="Abacavir" post="Nc1nc(NC2CC2)c2ncn(C3C CC(CO)C3)c2n1 131.51 417 Darunavir* CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)/N C(\O)O[C@H]1CO[C@H]2OCC[C@@H]12)S( O)( O)c1ccc(N)cc1"/>
 <result pre="Cc1cc(C CC#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1 228.94 628 Lomibuvir CC1CCC(C( O)N(c2cc(C#CC(C)(C)C)sc2C( O)O)C2CCC(O)CC2)CC1 280.96 703" exact="Penciclovir" post="Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 312.93 740 Triflurdine O c1[nH]c( O)n(C2CC(O)C(CO)O2)cc1C(F)(F)F 315.79"/>
 <result pre="Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 312.93 740 Triflurdine O c1[nH]c( O)n(C2CC(O)C(CO)O2)cc1C(F)(F)F 315.79 744" exact="Nevirapine" post="Cc1ccnc2c1NC( O)c1cccnc1N2C1CC1 367.50 812 Danoprevir* CC(C)(C)OC( O)N[C@H]1CCCCC/C C\[C@@H]2C[C@@]2(CNS( O)("/>
 <result pre="CC(C)(C)OC( O)N[C@H]1CCCCC/C C\[C@@H]2C[C@@]2(CNS( O)( O)C2CC2)NC( O)[C@@H]2C[C@@H](OC( O)N3Cc4cccc(F)c4C3)CN2C1 O 405.66 860" exact="Efavirenz" post="O C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1 406.33 862 Lamivudine Nc1ccn(C2CSC(CO)O2)c( O)n1 511.88 981"/>
 <result pre="O)[C@@H]2C[C@@H](OC( O)N3Cc4cccc(F)c4C3)CN2C1 O 405.66 860 Efavirenz O C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1 406.33 862" exact="Lamivudine" post="Nc1ccn(C2CSC(CO)O2)c( O)n1 511.88 981 Ritonavir CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1"/>
 <result pre="Efavirenz O C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1 406.33 862 Lamivudine Nc1ccn(C2CSC(CO)O2)c( O)n1 511.88 981" exact="Ritonavir" post="CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1 624.30 1077 Saquinavir CC(C)(C)NC( O)[C@@H]1C[C@@H]2CCCC[C@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC("/>
 <result pre="O)n1 511.88 981 Ritonavir CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1 624.30 1077" exact="Saquinavir" post="CC(C)(C)NC( O)[C@@H]1C[C@@H]2CCCC[C@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC( O)[C@H](CC(N) O)NC( O)c1ccc2ccccc2n1 704.86 1146 Ganciclovir* Nc1nc2c(ncn2COC(CO)CO)c("/>
 <result pre="O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2 CC C3N2N CN C3N)O)O)OC4 CC CC C4 6.48 32" exact="Daclatasvir" post="COC( O)NC(C( O)N1CCCC1c1ncc(—c2ccc(—c3ccc(-c4cnc(C5CCCN5C( O)C(NC( O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C 10.95 66 Danoprevir* CC(C)(C)OC("/>
 <result pre="Simeprevir* COc1ccc2c(O[C@H]3CC4C( O)N(C)CCCC/C C\[C@H]5C[C@@]5(C( O)NS( O)( O)C5CC5)NC( O)[C@@H]4C3)cc(—c3nc(C(C)C)cs3)nc2c1C 23.34 122" exact="Atazanavir" post="COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 25.92 136 Grazoprevir* C"/>
 <result pre="C CC1CC1(NC( O)C1CC(Oc2ncc(OC)c3ccc(Cl)cc23)CN1C( O)C(NC( O)OC(C)(C)C)C(C)(C)C)C( O)NS( O)( O)C1CC1 28.20 151" exact="Telaprevir" post="CCCC(NC( O)C1C2CCCC2CN1C( O)C(NC( O)C(NC( O)c1cnccn1)C1CCCCC1)C(C)(C)C)C( O)C( O)NC1CC1 40.75 194"/>
 <result pre="Telaprevir CCCC(NC( O)C1C2CCCC2CN1C( O)C(NC( O)C(NC( O)c1cnccn1)C1CCCCC1)C(C)(C)C)C( O)C( O)NC1CC1 40.75 194" exact="Ritonavir" post="CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1 41.60 196 Lopinavir* Cc1cccc(C)c1OCC( O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC("/>
 <result pre="O 78.49 295 Darunavir* CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)/N C(\O)O[C@H]1CO[C@H]2OCC[C@@H]12)S( O)( O)c1ccc(N)cc1 90.38 328" exact="Ganciclovir" post="Nc1nc( O)c2ncn(COC(CO)CO)c2[nH]1 108.21 365 Efavirenz* O C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 112.69 376"/>
 <result pre="Ganciclovir Nc1nc( O)c2ncn(COC(CO)CO)c2[nH]1 108.21 365 Efavirenz* O C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 112.69 376" exact="Penciclovir" post="Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 129.41 420 Etravirine Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br 175.50 522 Raltegravir"/>
 <result pre="Efavirenz* O C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 112.69 376 Penciclovir Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 129.41 420" exact="Etravirine" post="Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br 175.50 522 Raltegravir Cc1nnc(C( O)NC(C)(C)c2nc(C( O)NCc3ccc(F)cc3)c(O)c( O)n2C)o1 299.81"/>
 <result pre="O)n2C)o1 299.81 727 Dolutegravir CC1CCOC2Cn3cc(C( O)NCc4ccc(F)cc4F)c( O)c(O)c3C( O)N12 333.32 780" exact="Nelfinavir" post="Cc1c(O)cccc1C( O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C( O)NC(C)(C)C 365.96 823 Indinavir* CC(C)(C)NC( O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C( O)N[C@H]1c2ccccc2C[C@H]1O"/>
 <result pre="O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C( O)NC(C)(C)C 365.96 823 Indinavir* CC(C)(C)NC( O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C( O)N[C@H]1c2ccccc2C[C@H]1O 401.78 866" exact="Efavirenz" post="O C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1 412.86 880 Entecavir* C C1[C@@H](n2cnc3c( O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO 452.78"/>
 <result pre="CC1CCC(C( O)N(c2cc(C#CC(C)(C)C)sc2C( O)O)C2CCC(O)CC2)CC1 543.41 1049 Acyclovir Nc1nc( O)c2ncn(COCCO)c2[nH]1 661.76 1162" exact="Nevirapine" post="Cc1ccnc2c1NC( O)c1cccnc1N2C1CC1 864.38 1373 Table 4 Drug-target interaction (DTI)"/>
 <result pre="CC(C)(C)OC( O)N[C@H]1CCCCC/C C\[C@@H]2C[C@@]2(CNS( O)( O)C2CC2)NC( O)[C@@H]2C[C@@H](OC( O)N3Cc4cccc(F)c4C3)CN2C1 O 49.26 108" exact="Ganciclovir" post="Nc1nc( O)c2ncn(COC(CO)CO)c2[nH]1 56.29 122 Penciclovir Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 71.76 154"/>
 <result pre="O)[C@@H]2C[C@@H](OC( O)N3Cc4cccc(F)c4C3)CN2C1 O 49.26 108 Ganciclovir Nc1nc( O)c2ncn(COC(CO)CO)c2[nH]1 56.29 122" exact="Penciclovir" post="Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 71.76 154 Atazanavir COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC("/>
 <result pre="Ganciclovir Nc1nc( O)c2ncn(COC(CO)CO)c2[nH]1 56.29 122 Penciclovir Nc1nc( O)c2ncn(CCC(CO)CO)c2[nH]1 71.76 154" exact="Atazanavir" post="COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 82.36 164 Entecavir* C"/>
 <result pre="O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 82.36 164 Entecavir* C C1[C@@H](n2cnc3c( O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO 82.78 165" exact="Daclatasvir" post="COC( O)NC(C( O)N1CCCC1c1ncc(—c2ccc(—c3ccc(-c4cnc(C5CCCN5C( O)C(NC( O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C 110.47 200 Grazoprevir* C"/>
 <result pre="O)C1CC1 117.26 210 Lopinavir* Cc1cccc(C)c1OCC( O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC( O)[C@H](C(C)C)N1CCCNC1 O 163.61 275" exact="Ritonavir" post="CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1 182.51 297 Lomibuvir CC1CCC(C( O)N(c2cc(C#CC(C)(C)C)sc2C("/>
 <result pre="O)n2C)o1 306.99 427 Dolutegravir CC1CCOC2Cn3cc(C( O)NCc4ccc(F)cc4F)c( O)c(O)c3C( O)N12 326.89 451" exact="Abacavir" post="Nc1nc(NC2CC2)c2ncn(C3C CC(CO)C3)c2n1 346.10 466 Acyclovir Nc1nc( O)c2ncn(COCCO)c2[nH]1 406.63 520"/>
 <result pre="Abacavir Nc1nc(NC2CC2)c2ncn(C3C CC(CO)C3)c2n1 346.10 466 Acyclovir Nc1nc( O)c2ncn(COCCO)c2[nH]1 406.63 520" exact="Telaprevir" post="CCCC(NC( O)C1C2CCCC2CN1C( O)C(NC( O)C(NC( O)c1cnccn1)C1CCCCC1)C(C)(C)C)C( O)C( O)NC1CC1 686.16 725"/>
 <result pre="MT-DTI Rank out of 3411 Efavirenz* O C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 34.19 50" exact="Atazanavir" post="COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 50.32 77 Asunaprevir C"/>
 <result pre="Simeprevir* COc1ccc2c(O[C@H]3CC4C( O)N(C)CCCC/C C\[C@H]5C[C@@]5(C( O)NS( O)( O)C5CC5)NC( O)[C@@H]4C3)cc(—c3nc(C(C)C)cs3)nc2c1C 83.99 116" exact="Ritonavir" post="CC(C)c1nc(CN(C)C( O)NC(C( O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC( O)OCc2cncs2)C(C)C)cs1 124.36 150 Danoprevir* CC(C)(C)OC( O)N[C@H]1CCCCC/C"/>
 <result pre="O)O)C2CCC(O)CC2)CC1 398.81 367 Lopinavir* Cc1cccc(C)c1OCC( O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC( O)[C@H](C(C)C)N1CCCNC1 O 472.08 415" exact="Daclatasvir" post="COC( O)NC(C( O)N1CCCC1c1ncc(—c2ccc(—c3ccc(-c4cnc(C5CCCN5C( O)C(NC( O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C 478.02 420 Efavirenz O"/>
 <result pre="472.08 415 Daclatasvir COC( O)NC(C( O)N1CCCC1c1ncc(—c2ccc(—c3ccc(-c4cnc(C5CCCN5C( O)C(NC( O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C 478.02 420" exact="Efavirenz" post="O C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1 553.58 467 Darunavir* CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)/N C(\O)O[C@H]1CO[C@H]2OCC[C@@H]12)S( O)( O)c1ccc(N)cc1"/>
 <result pre="C1Nc2ccc(Cl)cc2C(C#CC2CC2)(C(F)(F)F)O1 553.58 467 Darunavir* CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)/N C(\O)O[C@H]1CO[C@H]2OCC[C@@H]12)S( O)( O)c1ccc(N)cc1 562.40 471" exact="Nelfinavir" post="Cc1c(O)cccc1C( O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C( O)NC(C)(C)C 576.82 479 Telaprevir CCCC(NC( O)C1C2CCCC2CN1C( O)C(NC("/>
 <result pre="O)( O)c1ccc(N)cc1 562.40 471 Nelfinavir Cc1c(O)cccc1C( O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C( O)NC(C)(C)C 576.82 479" exact="Telaprevir" post="CCCC(NC( O)C1C2CCCC2CN1C( O)C(NC( O)C(NC( O)c1cnccn1)C1CCCCC1)C(C)(C)C)C( O)C( O)NC1CC1 618.11 507"/>
 <result pre="Telaprevir CCCC(NC( O)C1C2CCCC2CN1C( O)C(NC( O)C(NC( O)c1cnccn1)C1CCCCC1)C(C)(C)C)C( O)C( O)NC1CC1 618.11 507" exact="Abacavir" post="Nc1nc(NC2CC2)c2ncn(C3C CC(CO)C3)c2n1 619.79 508 Raltegravir Cc1nnc(C( O)NC(C)(C)c2nc(C( O)NCc3ccc(F)cc3)c(O)c( O)n2C)o1"/>
 <result pre="C4 134.39 40 Dolutegravir CC1CCOC2Cn3cc(C( O)NCc4ccc(F)cc4F)c( O)c(O)c3C( O)N12 153.73 46" exact="Atazanavir" post="COC( O)NC(C( O)NC(Cc1ccccc1)C(O)CN(Cc1ccc(—c2ccccn2)cc1)NC( O)C(NC( O)OC)C(C)(C)C)C(C)(C)C 390.67 90 Efavirenz* O"/>
 <result pre="O)N1CC2C(C1C( O)NC(CC1CCC1)C( O)C(N) O)C2(C)C)C(C)(C)C 433.93 101 Among the prediction results," exact="atazanavir" post="was predicted to have a potential binding affinity to"/>
 <result pre="of the COVID-19 replication complex may be inhibited simultaneously by" exact="atazanavir" post="(Table 2, Table 3, Table 4, Table 5, Table"/>
 <result pre="2, Table 3, Table 4, Table 5, Table 6). Also," exact="ganciclovir" post="was predicted to bind to three subunits of the"/>
 <result pre="potential MERS therapeutics [28]. Recently, approximately $2 million worth of" exact="Kaletra" post="doses were donated to China [29], and a previous"/>
 <result pre="by inhibiting some aspects of SARS-CoV-2. For example, remdesivir and" exact="chloroquine" post="showed inhibitory effects against SARS-CoV-2 in vitro[31]. Another in-vitro"/>
 <result pre="effects against SARS-CoV-2 in vitro[31]. Another in-vitro study showed that" exact="hydroxychloroquine" post="was found to be more potent than chloroquine for"/>
 <result pre="showed that hydroxychloroquine was found to be more potent than" exact="chloroquine" post="for inhibiting SARS-CoV-2 [32]. Remdesivir and lopinavir/ritonavir (Kaletra) also"/>
 <result pre="but some differences were observed. For example, atazanavir, remdesivir, and" exact="efavirenz" post="were the top three predicted drugs that may bind"/>
 <result pre="3C-like proteinase of SARS-CoV-2. This is while saquinavir, nelfinavir, and" exact="grazoprevir" post="were the top three drugs identified by AutoDock Vina"/>
 <result pre="that these drugs may be effective in inhibiting SARS-CoV-2. Lastly," exact="atazanavir" post="appears to be effective in the treatment of COVID-19"/>
 <result pre="issue)17145705 15PaoliniG.V.ShaplandR.H.van HoornW.P.MasonJ.S.HopkinsA.L.Global mapping of pharmacological spaceNat Biotechnol247200680581516841068 16WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="treatment of SARS: initial virological and clinical findingsThorax593200425225614985565 31WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
</results>
